Observational Study of DME Following Scatter Laser Photocoagulation (PRP)

This study has been completed.
Sponsor:
Collaborator:
Information provided by:
Diabetic Retinopathy Clinical Research Network
ClinicalTrials.gov Identifier:
NCT00687154
First received: May 28, 2008
Last updated: March 18, 2011
Last verified: March 2011
  Purpose

The development or worsening of macular edema following full scatter photocoagulation is a well recognized occurrence. However, there is limited literature in this regard.

The purpose of this study is to determine the incidence and extent of macular edema following scatter laser photocoagulation surgery using optical coherence tomography (OCT) in eyes without macular edema prior to scatter laser photocoagulation and to explore whether the incidence and extent of macular edema varies according to the number of sittings included in the treatment regimen.

Study eyes will receive one of two types of scatter photocoagulation with results compared through use of OCT and photography images, as well as visual acuity testing.


Condition Intervention
Diabetic Macular Edema
Procedure: Scatter Laser Photocoagulation in 1 Sitting
Procedure: Scatter Laser Photocoagulation in 4 Sittings

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: An Observational Study of the Development of Diabetic Macular Edema Following Scatter Laser Photocoagulation

Resource links provided by NLM:


Further study details as provided by Diabetic Retinopathy Clinical Research Network:

Primary Outcome Measures:
  • Retinal thickening (measured with OCT) [ Time Frame: 34 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Visual Acuity (measured with E-ETDRS) [ Time Frame: 2 days, 4 weeks, 17, and 34 weeks ] [ Designated as safety issue: No ]

Enrollment: 155
Study Start Date: September 2005
Study Completion Date: January 2008
Primary Completion Date: January 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1 Sitting
Subjects with (1) OCT central subfield thickness ≤ 299 microns and (2) early proliferative or severe nonproliferative diabetic retinopathy for which investigator intends to perform full scatter photocoagulation in 1 sitting
Procedure: Scatter Laser Photocoagulation in 1 Sitting
1 sitting with a minimum of 1200 to a maximum of 1600 burns, with one burn width separation of burns and scatter extending from the peripheral arcades to beyond the equator.
Other Name: PRP
Active Comparator: 4 Sittings
Subjects with (1) OCT central subfield thickness ≤ 299 microns and (2) early proliferative or severe nonproliferative diabetic retinopathy for which investigator intends to perform full scatter photocoagulation in 4 sittings.
Procedure: Scatter Laser Photocoagulation in 4 Sittings
4 sittings, each separated by four weeks (+4 days), with approximately 300 burns in each of the first two sittings and investigator judgment for number of burns for the third and fourth sittings as long as the total for the four sittings is between 1200 and 1600 burns.
Other Name: PRP

Detailed Description:

Study eyes will receive scatter photocoagulation given by one of the following two regimens. To reduce selection bias, investigators will be required, prior to study initiation, to indicate which treatment (1 PRP sitting or 4 PRP sittings) they will administer. Only the selected treatment will be performed by a given investigator on study eyes.

  • 1 sitting with a minimum of 1200 to a maximum of 1600 burns, with one burn width separation of burns and scatter extending from the peripheral arcades to beyond the equator.
  • 4 sittings, each separated by four weeks (+4 days), with approximately 300 burns in each of the first two sittings and investigator judgment for number of burns for the third and fourth sittings as long as the total for the four sittings is between 1200 and 1600 burns.

Both of these regimens conform with usual clinical practice.

The study aims to enroll 150 eyes. At least 40 eyes will be enrolled with prior focal laser photocoagulation and at least 40 eyes without prior focal laser treatment. After enrollment of 80 eyes (40 with prior treatment and 40 without prior treatment), an interim analysis will be conducted so that focused enrollment strategies can be implemented if the analysis suggests that more subjects in a subgroup should be entered. Approximately half of the eyes will receive each scatter treatment regimen.

The following procedures will be done on the study eye at baseline and at each scheduled visit (except 8 and 12 weeks at which exam data are not collected) unless otherwise specified:

  • OCT
  • E-ETDRS visual acuity in both eyes (refraction in the study eye at baseline, 17 weeks, and 34 weeks)
  • Fundus photographs (7-fields at baseline and 3-fields at 34 weeks only)
  • Photographs to document the scatter photocoagulation (day of the first PRP sitting only)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria: To be eligible, the following inclusion (1-4) and exclusion criteria (5-8) must be met:

  1. Age >= 18 years

    • Patients <18 years old are not being included because there would be an insufficient number of patients <18 years old who would meet eligibility criteria for the study in order to be able to generalize the results to patients <18 years old or to provide informative data as to the effects of treatment in this age group.

  2. Diagnosis of diabetes mellitus (type 1 or type 2)

    • Any one of the following will be considered to be sufficient evidence that diabetes is present:

    1. Current regular use of insulin for the treatment of diabetes
    2. Current regular use of oral anti-hyperglycemia agents for the treatment of diabetes
    3. Documented diabetes by ADA and/or WHO criteria
  3. At least one eye meets the study eye criteria listed in section 2.2.2.
  4. Able and willing to provide informed consent.

    Exclusion Criteria: A patient is not eligible if any of the following exclusion criteria (5-8) are present:

  5. History of chronic renal failure requiring dialysis or kidney transplant.
  6. History of pancreatic transplant.
  7. A condition that, in the opinion of the investigator, would preclude participation in the study (e.g., unstable medical status including blood pressure and glycemic control).

    • Patients in poor glycemic control who, within the last 4 months, initiated intensive insulin treatment (a pump or multiple daily injections) or plan to do so in the next 4 months should not be enrolled.

  8. Patient is expecting to move out of the area of the clinical center to an area not covered by another clinical center during the next 8 months.

The patient must have at least one eye meeting all of the inclusion criteria (a-d) and none of the exclusion criteria (e-k) listed below.

A patient can have only one study eye. If both eyes are eligible, the investigator at his/her discretion will select one to be the study eye.

The eligibility criteria for a study eye are as follows:

Inclusion

  1. Presence of early proliferative or severe nonproliferative diabetic retinopathy for which investigator intends to perform full scatter photocoagulation in either one sitting or four sittings.
  2. Central subfield thickness on OCT ≤ 299 microns. Note: Clinically significant macular edema is not an exclusion provided the central subfield is ≤299 microns.
  3. Visual acuity 73 letters or greater (20/32 or better).
  4. Media clarity, pupillary dilation, and patient cooperation sufficient to administer full scatter photocoagulation and obtain adequate fundus photographs and OCT.

    Exclusion

  5. Prior scatter photocoagulation.
  6. High risk (severe proliferative) retinopathy.
  7. Presence of an ocular condition (other than diabetes) that, in the opinion of the investigator, might produce macular edema or alter visual acuity during the course of the study (e.g., vein occlusion, uveitis or other ocular inflammatory disease, neovascular glaucoma, Irvine-Gass Syndrome, significant vitreomacular interface disease, etc.).
  8. Treatment for diabetic macular edema is planned.
  9. History of any treatment for DME within prior 6 months, including focal/grid macular photocoagulation and corticosteroids by any route.
  10. History of major ocular surgery (including cataract extraction, vitrectomy, scleral buckle, any intraocular surgery, etc.) within prior 6 months or anticipated within the next 8 months following enrollment.
  11. History of YAG capsulotomy performed within 2 months prior to enrollment.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00687154

Sponsors and Collaborators
Diabetic Retinopathy Clinical Research Network
Investigators
Study Chair: Alexander J. Brucker, M.D. Scheie Eye Institute
  More Information

Publications:
Responsible Party: Roy W. Beck, M.D., Ph.D., Director, Jaeb Center for Health Research
ClinicalTrials.gov Identifier: NCT00687154     History of Changes
Other Study ID Numbers: NEI-127, U10EY018817-03, U10EY014229-07, U10EY014231-09
Study First Received: May 28, 2008
Last Updated: March 18, 2011
Health Authority: United States: Federal Government
United States: Institutional Review Board

Keywords provided by Diabetic Retinopathy Clinical Research Network:
DME
Laser
macular edema
retinopathy
scatter photocoagulation

Additional relevant MeSH terms:
Edema
Macular Edema
Eye Diseases
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Signs and Symptoms

ClinicalTrials.gov processed this record on October 23, 2014